3D 바이오프린팅 시장 규모, 점유율 및 동향 분석 보고서 : 기술별, 용도별, 지역별 및 부문별 예측(2026-2033년)

3D Bioprinting Market Summary

The global 3D bioprinting market size was valued at USD 3.07 billion in 2025 and is projected to reach USD 6.67 billion by 2033, growing at CAGR of 9.71% from 2026 to 2033. The growth of 3D bioprinting is driven by the increasing demand for advanced tissue-engineering and regenerative-medicine solutions, particularly for organ transplantation and personalized treatments.

Rising investments in research, along with technological advancements in biomaterials and printing techniques, are accelerating innovation in this field. In addition, the need for more accurate drug testing models and reduced reliance on animal testing is further supporting market expansion.

The increasing demand for regenerative medicine is a key driver of the 3D bioprinting market, as it enables the development of functional tissues and potential organ substitutes for damaged or diseased body parts. Bioprinting technology supports the creation of patient-specific tissues, improving treatment outcomes and reducing the risk of rejection. As chronic diseases and organ failure cases rise, the need for advanced therapeutic solutions continues to grow. This trend is accelerating research and investment in bioprinting technologies, driving overall market expansion.

For instance, in June 2025, a team of international scientists announced a significant breakthrough in diabetes research, successfully 3D-printing functional human islets using an advanced bioink. The innovation, presented at a major scientific forum, highlights the potential to develop more effective, minimally invasive treatment options for individuals with type 1 diabetes (T1D).

"Our goal was to recreate the natural environment of the pancreas so that transplanted cells would survive and function better," explained lead author Dr. Quentin Perrier. "We used a special bioink that mimics the support structure of the pancreas, giving islets the oxygen and nutrients they need to thrive."

"This is one of the first studies to use real human islets instead of animal cells in bioprinting, and the results are incredibly promising," noted Dr. Perrier. "It means we're getting closer to creating an off-the-shelf treatment for diabetes that could one day eliminate the need for insulin injections."

"While there is still work to be done, this new bioprinting method marks a critical step toward personalised, implantable therapies for diabetes. If clinical trials confirm its effectiveness, it could transform treatment and quality of life for millions of people worldwide," Dr. Perrier concluded.

The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer is driving the 3D bioprinting market by creating a greater need for advanced treatment and disease management solutions. Bioprinting enables the development of realistic tissue models for studying disease progression and testing drugs more effectively. It also supports the creation of customized implants and regenerative therapies tailored to patient needs. As the global burden of chronic conditions rises, demand for innovative, precise healthcare technologies such as bioprinting continues to grow.

Furthermore, the expanding focus on personalized medicine is a key driver of the 3D bioprinting market, as it enables the creation of patient-specific tissues and models tailored to individual biological characteristics. Bioprinting enables more precise drug testing and customized treatment, improving therapeutic outcomes and reducing adverse effects. The increasing demand for targeted therapies, especially in oncology and chronic diseases, is accelerating the adoption of this technology. This trend is encouraging continuous innovation and investment in advanced bioprinting solutions. For instance, in October 2025, ScienceDirect highlighted that 3D bioprinting is playing a crucial role in advancing personalized medicine by enabling the development of patient-specific drug delivery systems, customized dosage forms, and multidrug polypills. These capabilities allow treatments to be tailored to individual patient needs, improving therapeutic outcomes and adherence. As a result, the growing emphasis on precision and individualized healthcare is significantly driving the adoption of 3D bioprinting technologies in the medical field.

Global 3D Bioprinting Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global 3D bioprinting market report based on technology, application, and region:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Magnetic Levitation
• Inkjet-based
• Syringe-based
• Laser-based
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Medical
  • Tissue and organ generation
  • Medical pills
  • Prosthetics and implants
  • Others
• Dental
• Biosensors
• Consumer/Personal Product Testing
• Bioinks
• Food and Animal Product
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Technology
  • 1.1.2. Application
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. 3D Bioprinting Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising demand for regenerative medicine
    • 3.2.1.2. Increasing focus on personalized medicine
    • 3.2.1.3. Technological advancements
    • 3.2.1.4. Expanding applications in cancer research and disease modeling
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of bioprinters, biomaterials, and maintenance
    • 3.2.2.2. Complexity of technology
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Development of bioprinted organs for transplantation
    • 3.2.3.2. Expansion in pharmaceutical and cosmetic testing
    • 3.2.3.3. Emerging applications in regenerative medicine
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Difficulty in replicating complex tissue structures
• 3.3. 3D Bioprinting Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. 3D Bioprinting Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global 3D Bioprinting Market: Technology Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global 3D Bioprinting Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 4.4. Inkjet-based
  • 4.4.1. Inkjet-based market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Magnetic Levitation
  • 4.5.1. Magnetic levitation market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Syringe-based
  • 4.6.1. Syringe-based market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Laser-based
  • 4.7.1. Laser-based market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. 3D Bioprinting Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global 3D Bioprinting Market: Application Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global 3D Bioprinting Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
• 5.4. Medical
  • 5.4.1. Medical market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Tissue and organ generation
    • 5.4.2.1. Tissue and organ generation market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Medical pills
    • 5.4.3.1. Medical pills market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Prosthetics and implants
    • 5.4.4.1. Prosthetics and implants market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Others
    • 5.4.5.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Dental
  • 5.5.1. Dental market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Biosensors
  • 5.6.1. Biosensors market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Consumer/Personal Product Testing
  • 5.7.1. Consumer/personal product testing market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Bioinks
  • 5.8.1. Bioinks market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.9. Food and Animal Product
  • 5.9.1. Food and animal product market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. 3D Bioprinting Market: Regional Estimates & Trend Analysis by Technology and Application

• 6.1. Regional Dashboard
• 6.2. Market Size and Trend Analysis, 2021 to 2033
• 6.3. North America
  • 6.3.1. North America 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Competitive scenario
    • 6.3.2.3. Regulatory framework
    • 6.3.2.4. Reimbursement scenario
    • 6.3.2.5. U.S. 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Competitive scenario
    • 6.3.3.3. Regulatory framework
    • 6.3.3.4. Reimbursement scenario
    • 6.3.3.5. Canada 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Competitive scenario
    • 6.3.4.3. Regulatory framework
    • 6.3.4.4. Reimbursement scenario
    • 6.3.4.5. Mexico 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Competitive scenario
    • 6.4.2.3. Regulatory framework
    • 6.4.2.4. Reimbursement scenario
    • 6.4.2.5. UK 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Competitive scenario
    • 6.4.3.3. Regulatory framework
    • 6.4.3.4. Reimbursement scenario
    • 6.4.3.5. Germany 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Competitive scenario
    • 6.4.4.3. Regulatory framework
    • 6.4.4.4. Reimbursement scenario
    • 6.4.4.5. France 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Competitive scenario
    • 6.4.5.3. Regulatory framework
    • 6.4.5.4. Reimbursement scenario
    • 6.4.5.5. Italy 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Competitive scenario
    • 6.4.6.3. Regulatory framework
    • 6.4.6.4. Reimbursement scenario
    • 6.4.6.5. Spain 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Competitive scenario
    • 6.4.7.3. Regulatory framework
    • 6.4.7.4. Reimbursement scenario
    • 6.4.7.5. Sweden 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Competitive scenario
    • 6.4.8.3. Regulatory framework
    • 6.4.8.4. Reimbursement scenario
    • 6.4.8.5. Denmark 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Competitive scenario
    • 6.4.9.3. Regulatory framework
    • 6.4.9.4. Reimbursement scenario
    • 6.4.9.5. Norway 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. China 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Japan
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Competitive scenario
    • 6.5.3.3. Regulatory framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Japan 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Competitive scenario
    • 6.5.4.3. Regulatory framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. India 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Competitive scenario
    • 6.5.5.3. Regulatory framework
    • 6.5.5.4. Reimbursement scenario
    • 6.5.5.5. South Korea 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Australia
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Competitive scenario
    • 6.5.6.3. Regulatory framework
    • 6.5.6.4. Reimbursement scenario
    • 6.5.6.5. Australia 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Competitive scenario
    • 6.5.7.3. Regulatory framework
    • 6.5.7.4. Reimbursement scenario
    • 6.5.7.5. Thailand 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Brazil 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Competitive scenario
    • 6.6.3.3. Regulatory framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. Argentina 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Middle East and Africa
  • 6.7.1. Middle East and Africa 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. South Africa 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. Saudi Arabia 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Competitive scenario
    • 6.7.4.3. Regulatory framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. UAE 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Competitive scenario
    • 6.7.5.3. Regulatory framework
    • 6.7.5.4. Reimbursement scenario
    • 6.7.5.5. Kuwait 3D bioprinting market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Market Share Analysis, 2025
• 7.4. Company Heat Map Analysis
• 7.5. Strategy Mapping
  • 7.5.1. Expansion
  • 7.5.2. Mergers & Acquisition
  • 7.5.3. Partnerships & Collaborations
  • 7.5.4. New Technology Launches
  • 7.5.5. Research And Development
  • 7.5.6. Company Profiles
  • 7.5.7. Organovo Holdings, Inc.
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. CELLINK
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. 3D Systems, Inc.
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Desktop Metal, Inc. (Nano Dimension Ltd.)
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic initiatives
  • 7.5.11. Aspect Biosystems Ltd.
    • 7.5.11.1. Company overview
    • 7.5.11.2. Financial performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic initiatives
  • 7.5.12. regenHU
    • 7.5.12.1. Company overview
    • 7.5.12.2. Financial performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic initiatives
  • 7.5.13. CYFUSE
    • 7.5.13.1. Company overview
    • 7.5.13.2. Financial performance
    • 7.5.13.3. Product Benchmarking
    • 7.5.13.4. Strategic initiatives
  • 7.5.14. CollPlant
    • 7.5.14.1. Company overview
    • 7.5.14.2. Financial performance
    • 7.5.14.3. Product Benchmarking
    • 7.5.14.4. Strategic initiatives
  • 7.5.15. Regemat 3D.
    • 7.5.15.1. Company overview
    • 7.5.15.2. Financial performance
    • 7.5.15.3. Product Benchmarking
    • 7.5.15.4. Strategic initiatives
  • 7.5.16. 3D Bioprinting Solutions
    • 7.5.16.1. Company overview
    • 7.5.16.2. Financial performance
    • 7.5.16.3. Product Benchmarking
    • 7.5.16.4. Strategic initiatives
  • 7.5.17. Allevi, Inc.
    • 7.5.17.1. Company overview
    • 7.5.17.2. Financial performance
    • 7.5.17.3. Product Benchmarking
    • 7.5.17.4. Strategic initiatives
  • 7.5.18. Poietis
    • 7.5.18.1. Company overview
    • 7.5.18.2. Financial performance
    • 7.5.18.3. Product Benchmarking
    • 7.5.18.4. Strategic initiatives
  • 7.5.19. Inventia Life Science Pty Ltd.
    • 7.5.19.1. Company overview
    • 7.5.19.2. Financial performance
    • 7.5.19.3. Product Benchmarking
    • 7.5.19.4. Strategic initiatives